Lenvima 4 mg Capsules contain Lenvatinib, a targeted cancer therapy used in the treatment of advanced thyroid cancer, renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC). It belongs to a class of medications known as tyrosine kinase inhibitors (TKIs), which block specific enzymes involved in the growth and spread of cancer cells. This 4 mg strength is often used alone or in combination with other strengths to achieve the prescribed daily dose.

• Slows or halts the growth of cancer cells in thyroid, kidney, and liver cancers

• Improves progression-free survival in patients with advanced disease

• Used in combination with other medications (e.g., pembrolizumab) for RCC

• Oral administration offers convenience over injectable chemotherapy

• Proven efficacy in radioiodine-refractory differentiated thyroid cancer (RR-DTC)

• Take Lenvima capsules orally with or without food, at the same time each day

• Swallow the capsule whole with water; do not open or crush

• Follow your oncologist’s instructions regarding dose combination (e.g., multiple strengths)

• Adhere strictly to the prescribed schedule; do not change or skip doses

• The usual starting dose and schedule depend on cancer type and patient tolerance

  • For thyroid cancer: 24 mg once daily (can be achieved using combinations like 4 mg + 10 mg)

  • For RCC (with pembrolizumab): 20 mg once daily

  • For HCC (based on body weight): 8 mg or 12 mg once daily

• Dose adjustments may be required for side effects or organ function changes

• Your doctor may combine 4 mg capsules with other strengths to reach the exact required dose

• Inform your doctor of any history of hypertension, liver/kidney disorders, bleeding issues, or heart disease

• Monitor blood pressure, liver function, and ECGs regularly during treatment

• Not recommended during pregnancy or breastfeeding

• Use effective contraception during treatment and for at least 1 month after the last dose

• Avoid grapefruit juice as it may interact with the drug’s metabolism

Common and serious side effects may include:

• High blood pressure (hypertension)

• Fatigue, diarrhea, loss of appetite

• Weight loss, nausea, vomiting

• Protein in urine, joint or muscle pain

• Serious: arterial thromboembolism, liver dysfunction, kidney impairment, QT prolongation, gastrointestinal perforation

Seek immediate medical attention for chest pain, vision changes, unusual bleeding, or severe abdominal pain.

• Store below 30°C (86°F) in a dry place

• Keep capsules in their original packaging until use

• Protect from moisture and heat

• Keep out of reach of children

• Do not use expired or damaged capsules

Q1. What is Lenvima 4 mg used for?
Lenvima 4 mg is used as part of a targeted therapy regimen for advanced thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.

Q2. Can Lenvima be used as monotherapy?
Yes, it is used alone in thyroid cancer and liver cancer, and in combination with pembrolizumab in kidney cancer.

Q3. How long should I take Lenvima?
Continue treatment as long as it is effective and well-tolerated, or until your doctor advises otherwise.

Q4. What should I do if I miss a dose?
Take it as soon as possible if within 12 hours of the usual time. Skip it if more than 12 hours late. Do not double the dose.

Q5. Is Lenvima chemotherapy?
Lenvima is a targeted therapy, not traditional chemotherapy. It interferes with cancer cell growth by blocking tyrosine kinases.